| letrozole vs aminoglutethimide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| clinical benefit | 0.81 [0.52 1.25] | p=1.00 | 0 | 363 | 1 | Gershanovich, | | objective response (ORR) | 0.64 [0.36 1.13] | p=1.00 | 0 | 363 | 1 | Gershanovich, | | progression or death (progression free survival PFS) | 0.72 [0.36 1.43] | p=1.00 | 0 | -18 | 1 | Gershanovich, | | hot flushes | no data | | rash | no data | | vaginal bleeding | no data | | thromboembolic AE | no data | | arthralgia | no data | | vomiting | no data | | diarrhoea | no data | | nausea | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| letrozole vs anastrozole | No demonstrated result suggested objective response (ORR) by 35% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| clinical benefit | 0.85 [0.61 1.20] | p=1.00 | 0 | 713 | 1 | Rose, | | objective response (ORR) | 0.65 [0.43 0.97] | p=0.04 | 0 | 713 | 1 | Rose, | | hot flushes | no data | | rash | no data | | vaginal bleeding | no data | | thromboembolic AE | no data | | arthralgia | no data | | vomiting | no data | | diarrhoea | no data | | nausea | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| letrozole vs atamestane + toremifene | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| clinical benefit | 0.96 [0.74 1.26] | p=1.00 | 0 | 865 | 1 | Goss, | | objective response (ORR) | 0.85 [0.64 1.13] | p=1.00 | 0 | 865 | 1 | Goss, | | progression or death (progression free survival PFS) | 1.00 [0.67 1.49] | p=1.00 | 0 | -18 | 1 | Goss, | | hot flushes | no data | | rash | no data | | vaginal bleeding | no data | | thromboembolic AE | no data | | arthralgia | no data | | vomiting | no data | | diarrhoea | no data | | nausea | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| letrozole vs fadrozole | No demonstrated result suggested objective response (ORR) by 58% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| clinical benefit | 0.70 [0.37 1.33] | p=1.00 | 0 | 157 | 1 | Tominaga, | | objective response (ORR) | 0.42 [0.19 0.96] | p=0.04 | 0 | 157 | 1 | Tominaga, | | hot flushes | no data | | rash | no data | | vaginal bleeding | no data | | thromboembolic AE | no data | | arthralgia | no data | | vomiting | no data | | diarrhoea | no data | | nausea | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| letrozole vs megestrol acetate | No demonstrated result suggested vaginal bleeding by 92% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| clinical benefit | 0.90 [0.66 1.23] | p=1.00 | 0 | 763 | 2 | Buzdar,Dombernowsky, | | objective response (ORR) | 0.84 [0.58 1.23] | p=1.00 | 0 | 742 | 2 | Buzdar,Dombernowsky, | | death (overall survival) | 0.87 [0.53 1.43] | p=1.00 | 0 | -36 | 2 | Buzdar,Dombernowsky, | | progression or death (progression free survival PFS) | 0.99 [0.61 1.59] | p=1.00 | 0 | -36 | 2 | Buzdar,Dombernowsky, | | hot flushes | 1.10 [0.66 1.83] | p=1.00 | 0 | 763 | 2 | Buzdar,Dombernowsky, | | rash | 1.81 [0.64 5.09] | p=1.00 | 0 | 363 | 1 | Dombernowsky, | | vaginal bleeding | 0.08 [0.01 0.65] | p=0.04 | 0 | 400 | 1 | Buzdar, | | thromboembolic AE | no data | | arthralgia | 1.67 [0.84 3.31] | p=1.00 | 0 | 363 | 1 | Dombernowsky, | | vomiting | 1.41 [0.60 3.31] | p=1.00 | 0 | 363 | 1 | Dombernowsky, | | diarrhoea | 1.66 [0.73 3.76] | p=1.00 | 0 | 763 | 2 | Buzdar,Dombernowsky, | | nausea | 1.16 [0.72 1.87] | p=1.00 | 0 | 763 | 2 | Buzdar,Dombernowsky, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| letrozole vs tamoxifen | No demonstrated result diarrhoea by 800% (harmful effect) suggested objective response (ORR) by 33% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| clinical benefit | 0.78 [0.60 1.02] | p=1.00 | 0 | 907 | 1 | Mourisden, | | objective response (ORR) | 0.67 [0.49 0.91] | p=0.04 | 0 | 907 | 1 | Mourisden, | | progression or death (progression free survival PFS) | 0.70 [0.40 1.22] | p=1.00 | 0 | -18 | 1 | Mourisden, | | rash | no data | | vaginal bleeding | no data | | thromboembolic AE | no data | | hot flushes | 1.14 [0.81 1.60] | p=1.00 | 0 | 910 | 1 | Mourisden, | | arthralgia | 1.06 [0.74 1.52] | p=1.00 | 0 | 910 | 1 | Mourisden, | | vomiting | no data | | diarrhoea | 9.00 [1.14 71.33] | p=0.04 | 0 | 910 | 1 | Mourisden, | | nausea | 1.01 [0.72 1.43] | p=1.00 | 0 | 910 | 1 | Mourisden, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
